Free tool
Stocks listed on XETRA
We cover 22 companies listed on XETRA. The median market value in the group is $9.16B. Across the group, the median move over the past trading day is +1.03%. 81% of the 21 with a 200-day average trade above it. Price change over the past year runs from −23.3% to +69.5% across the middle 80 percent of the group, with a median of +21.5%.
Other lists in this group
Table
22 of 1,273 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −6.73% |
| OBCK.DE | Ottobock SE & Co. KGaA | $4.40B | Mid cap | +0.68% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% |
| FIE.DE | Fielmann Group AG | $3.79B | Mid cap | −27.31% |
| 22Z.DE | Zealand Pharma A/S | $3.37B | Mid cap | −28.16% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.